GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, as successful results may enhance the company’s position in the oncology market. The involvement of ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...